LYCOS RETRIEVER 
King Pharmaceuticals: Products
built 630 days ago
Under the terms of the Agreement, King will make an upfront cash payment to Acura of $30 million. Depending on the achievement of certain development and regulatory milestones, King could ... make additional cash payments to Acura of up to $28 million relating to ACUROX(TM) Tablets and similar amounts with respect to each subsequent Aversion(R) Technology product developed under the Agreement. King will reimburse Acura for all research and development expenses incurred beginning from September 19, 2007 for ACUROX(TM) Tablets and all research and development expenses related to future products after King's exercise of its option to an exclusive license for each future product. King will record net sales of all products and pay Acura a royalty ranging from 5% to 25% based on the level of combined annual net sales for all products subject to the Agreement. King will also make a one-time cash payment to Acura of $50 million in the first year in which the combined annual net sales of all products exceed $750 million.
Source:
("FDA") pertaining to King's product, AVINZA(R) (morphine sulfate extended release). Allegations of non-infringement in Actavis's Paragraph IV Certification relate to U.S. Patent No. 6,066,339 ("the '339 Patent"). The '339 Patent is a utility patent that covers the formulation of AVINZA (R). King, a licensee of the '339 Patent, intends to vigorously enforce the patent. The '339 Patent extends through November 25, 2017.
Source:
King ... has binodenoson (currently in Phase III) the next generation cardiac pharmacologic stress-imaging agent to replace Adenosine. There isn't much information on this product as management is keeping things close to their chest due to a competitor's product which is running in parallel with binodenoson in the approval race.
Source:
MORE ABOUT
Products